NeuroPace (NPCE) Q3 2026 earnings review
NeuroPace cuts its sales outlook as implant growth stalls
NeuroPace, the maker of a brain implant that stops epileptic seizures, saw its sales growth stall after changes to its sales team disrupted its largest hospital accounts. Implant revenue edged up 1% from a year ago after growing 21% last quarter, while lower sales commissions and higher factory margins produced a small operating profit. Chief executive Joel Becker cut the full-year revenue outlook by $9 million, which by our math leaves fourth-quarter implant growth at 5%.
| RNS System implant sales | $22.9M +1.4% from a year ago (vs +21% last quarter) |
|---|---|
| Gross margin, excluding one-offs | 84.8% +2.0 percentage points from a year ago |
| Adjusted EBITDA | $0.4M $-1.3M a year ago |
| Full-year revenue outlook | Cut $9M to $91–92M (10–11% implant growth) |
⚖️ Verdict: 🔴 Bearish
The story got worse because both pillars of the growth case — steady 20% implant growth in its current market and a mid-2026 FDA expansion into generalized epilepsy — broke in the same quarter. After an October meeting to resolve FDA questions, NeuroPace won't file its amended generalized epilepsy application until around year-end. One bright spot: gross margin excluding one-offs reached 85%, and the company raised its full-year margin plan.
The question now is whether the third-quarter stall was a brief disruption from reorganizing the sales force or the start of saturation at top epilepsy centers. If it was just territory turnover, scheduled surgeries will rebound; if top hospitals are tapped out, growth stays below the old 20% floor. The initial 2027 revenue outlook next spring will settle it.
🐂 Bull Case
Factory Efficiency Lifted Gross Margin Near 85%
NeuroPace makes the RNS System, a brain-responsive implant that stops seizures in epilepsy patients. After dropping a lower-margin distribution business last year, the medical device maker now keeps nearly 85 cents of every sales dollar after manufacturing costs. Gross margin excluding one-offs rose 2.0 percentage points from a year ago to 84.8% because of "improved labor absorption" at its plant, the company said.
That manufacturing efficiency prompted NeuroPace to raise its full-year gross margin outlook by 0.75 percentage points at the middle of the range, to 83.0–83.5%, even as it lowered its sales plan.
What to watch: fourth-quarter gross margin excluding one-offs, which the full-year plan puts at 82.3% by our math. Holding above 83% while implant volume is slow would show the factory gains are permanent.
Lower Sales Commissions Produced Positive Operating Profit
Even though revenue slipped 1.1% from a year ago, NeuroPace generated $0.4 million in operating profit excluding one-offs, reversing a $1.4 million loss in the prior-year period. Operating expenses excluding stock compensation fell by 5.5 percentage points of revenue because the sales shortfall triggered an automatic drop in variable pay.
- Sales and marketing excluding one-offs: 45.5% of revenue, down 2.7 percentage points from a year ago on a "decrease in sales and field support personnel costs, including sales commissions"
- General and administrative excluding one-offs: 13.9% of revenue, down 2.1 percentage points on lower variable compensation
- Research and development excluding one-offs: 23.9% of revenue, down 0.8 percentage points
What to watch: fourth-quarter operating expenses excluding one-offs, which the full-year outlook puts at $22.9 million by our math, up from $19.2 million this quarter. A smaller increase would keep full-year cash losses in check.
Telehealth Filing and Teen Study Advance Pipeline
Patients with the RNS System currently travel to specialized epilepsy centers so doctors can adjust their implant settings. This quarter NeuroPace asked the Food and Drug Administration (FDA) to approve Remote Care, software that lets physicians "program the RNS System through telehealth" under a planned 180-day review.
The epilepsy device maker also began enrolling patients in AURORA, a study to expand its focal epilepsy approval — seizures starting in one area of the brain — to adolescents aged 12 to 17. It expects to finish collecting data in early 2027.
What to watch: FDA clearance for Remote Care around the second quarter of 2027. Approval would let doctors manage patients who live far from specialized hospitals, removing a barrier to new implants.
🐻 Bear Case
Sales Team Disruption Stalled Implant Growth
"Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates," chief executive Joel Becker said. Sales of the RNS System — the brain implant that generates nearly all company revenue — grew 1.4% from a year ago to $22.9 million, down from 21.3% growth in the second quarter.
Becker blamed "isolated account-level issues and changes to our field organization that created more disruption than anticipated" at several of its largest hospital accounts, and noted that "fourth-quarter scheduled cases have begun to recover". Yet the numbers in the revised full-year outlook cut against the idea of a fast rebound.
NeuroPace cut its 2026 revenue plan by $9 million at the middle of the range, taking full-year RNS System growth down from 21–23% to 10–11%. By our math, that outlook leaves fourth-quarter RNS System sales at $23.4 million at the middle of the range, or 4.5% growth from a year ago — less than a quarter of the pace the business ran at in the first half.
What to watch: first-quarter 2027 revenue and the initial 2027 full-year outlook next spring. Because sales force changes take one to two quarters of hospital scheduling to work through, only the 2027 plan will show whether the top epilepsy centers have resumed their prior implant pace.
FDA Questions Push Generalized Epilepsy Filing to Year-End
NeuroPace wants FDA approval to sell the RNS System for idiopathic generalized epilepsy (IGE), a form of the disease where seizures affect both sides of the brain at once. Earlier this year management aimed for an FDA decision in mid-2026, even after its clinical trial missed its primary efficacy target while meeting safety and secondary goals.
That timeline has slipped into 2027. The device maker completed a Submission Issue Request (SIR) meeting — a formal session to resolve agency review deficiencies — with the FDA in October, and now plans to submit an amended application around the end of 2026.
Because private insurance coverage takes months to put in place after the FDA acts, pushing the amendment to year-end moves meaningful revenue from the expanded patient pool out by at least another year.
What to watch: confirmation on the fourth-quarter call that the IGE amendment went to the FDA on time, along with the length of the agency's new review clock.
Service Revenue Dropped While Inventory Built Up
Alongside its implants, NeuroPace earns service revenue by sharing its database of brain recordings with drug companies. Service revenue fell 74% from a year ago to $0.2 million in the third quarter, pulling total revenue down 1.1% despite the slight gain in implant sales.
At the same time, slower implant sales left more devices on the shelf. Operating cash outflow widened to $2.8 million from $1.9 million a year ago because the company put another $0.9 million into inventory during the quarter.
What to watch: fourth-quarter operating cash flow, as the full-year outlook points to a $3.4 million Adjusted EBITDA loss in the final quarter by our math.
💲 Other KPIs
Cash, short-term investments and restricted cash fell by $2.5 million from last quarter and by $11.7 million since the start of the year. NeuroPace holds $59.2 million in long-term debt, leaving it with $9.7 million more debt than cash by our math.
Stockpiled components and finished devices rose 26.5% from $14.9 million at the end of 2025, and climbed 3.7% from $18.1 million last quarter. Building inventory while hospital implant orders stalled tied up $2.2 million of cash over the first nine months of the year.
The share count rose 3.7% from 33.1 million a year ago and 0.7% from 34.1 million in the second quarter, driven by employee stock plans.
🔮 Guidance
Cut. The middle of the range dropped by $9.0 million to 8.4% growth for the year, reversing two earlier raises of $1.0 million and $0.5 million. Within the total, RNS System implant growth falls to 10–11% from 21–23% previously, while service revenue stays at about $1 million. By our math, that leaves fourth-quarter total revenue up 1.3% and RNS System sales up 4.5% from a year ago.
Raised. NeuroPace lifted the range by 0.75 percentage points at the middle on better factory labor absorption. It is the second straight raise after a 0.5-point increase last quarter. By our math, the full-year target points to a fourth-quarter gross margin of about 82.3%, down from 84.8% in the third quarter.
Cut. Management reduced planned operating costs by $5.5 million at the middle of the range, excluding about $10 million in stock-based pay, as lower sales shrink commission payouts. By our math, that leaves $22.9 million of spending for the fourth quarter, up 16.4% from a year ago.
Cut. The expected full-year operating cash loss widened by $1.0 million at the middle of the range, giving back last quarter's $1.0 million improvement. Lower sales commissions and higher factory margins offset most, but not all, of the $9.0 million revenue cut. By our math, the plan leaves a $3.4 million Adjusted EBITDA loss in the fourth quarter.
❓ Key Questions
What went wrong at the largest hospital accounts?
Chief executive Joel Becker cited isolated account issues and field-organization changes for the slowdown from 21% implant growth to 1%. Investors need to know whether the company lost sales reps, redrew territories, or saw doctors switch to rival therapies.
What did the FDA ask for in the October meeting?
The clinical trial for generalized epilepsy missed its primary efficacy goal earlier, and NeuroPace just held a formal issue-resolution meeting with the FDA. Management did not say whether the agency asked for new data analyses or a narrower patient label in the year-end amendment.
Why does the fourth-quarter cost plan jump by $3.7 million?
By our math, the full-year outlook points to $22.9 million in fourth-quarter operating expenses excluding one-offs, up from $19.2 million in the third quarter, even though implied revenue barely moves. Management has not explained what drives that spending step-up.
How are active prescriber counts and the patient funnel trending?
In prior quarters NeuroPace highlighted record numbers of prescribing doctors, active hospital accounts and patients in the pipeline. The third-quarter release omitted those indicators, leaving unclear whether demand slowed beyond the largest accounts.